Related Experiment Videos

Fluvastatin reduced major adverse cardiac outcomes after first percutaneous coronary intervention

Robert A Harrington¹

¹Duke University Medical Center, Durham, North Carolina, USA.

ACP Journal Club

|January 4, 2003

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.

Circulation·2019

Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.

Journal of the American College of Cardiology·2019

Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention.

Circulation. Cardiovascular interventions·2019

Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial.

American heart journal·2019

Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.

Circulation. Cardiovascular interventions·2019

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

The lancet. Diabetes & endocrinology·2019

See all related articles